APOE and Alzheimer disease: Differential APOE genotype effects have also been reported for the treatment of mild-to-moderate AD patients using the diabetes drug rosiglitazone, with APOE4− AD patients, but not APOE4+ AD patients, showing cognitive improvement [128].